CDK4/6 Inhibitors for Medulloblastoma Treatment
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma
Recruiting
Early Phase 1
Interventional Study
Medulloblastoma, Childhood
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 0 – 18
- Sex
- Any
- Trial phase
- Early Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 60 (estimated)
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Other
Who this trial is looking for
This trial is looking for children who have had surgery for medulloblastoma, a type of brain tumor. Participants will help researchers learn more about new treatments for this condition.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with medulloblastoma.
- I had surgery for my medulloblastoma at the Pediatric Neurosurgery Unit.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Medulloblastoma (MB), a rare yet critical pediatric brain tumor, is divided into 4 molecular subgroups (WNT, SHH, Group 3, Group 4), each with distinct genetic profiles. Despite diagnostic and therapeutic advances, neurotoxicity from standard treatments (resection, radiotherapy, chemotherapy) and the need for long-term care remain challenges. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* All patients affected by Medulloblastoma operated on at the Pediatric Neurosurgery Unit during their pediatric age will be elected to take part to the study
Contacts